



## Y15

<b>Cat. No.:</b>	HY-12444
<b>CAS No.:</b>	4506-66-5
<b>Molecular Formula:</b>	C <sub>6</sub> H <sub>4</sub> Cl <sub>4</sub> N <sub>4</sub>
<b>Molecular Weight:</b>	284
<b>Target:</b>	FAK
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 50 mg/mL (176.06 mM; ultrasonic and warming and heat to 50°C)					
	DMSO : 25 mg/mL (88.03 mM; ultrasonic and warming and heat to 60°C)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		3.5211 mL	17.6056 mL	35.2113 mL
<b>5 mM</b>			0.7042 mL	3.5211 mL	7.0423 mL	
<b>10 mM</b>		0.3521 mL	1.7606 mL	3.5211 mL		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 10 mg/mL (35.21 mM); Clear solution; Need ultrasonic and warming and heat to 60°C					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Y15 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.
<b>IC<sub>50</sub> &amp; Target</b>	FAK <sup>[1]</sup>
<b>In Vitro</b>	Y15 directly blocks autophosphorylation activity of FAK. Y15 inhibits Y397 phosphorylation of FAK starting at 0.1 μM in Panc-1 cells. At a dose of 100 μM, Y15 has the same or better inhibition as TAE226. Of note, total FAK is downregulated at higher doses of Y15. Y15 also blocks phosphorylation of the FAK downstream substrate, paxillin. Total paxillin is decreased at higher doses similar to FAK. Thus, Y15 inhibits FAK phosphorylation in a dose-dependent manner <sup>[1]</sup> . MTS assay is completed using a range of Y15 doses on all cell lines (TT, K1, BCPAP, and TPC1, respectively). Y15 inhibited cell viability in a dose-dependent manner across all thyroid cell lines evaluated. IC <sub>50</sub> is 2.05, 5.74, 9.99, and 17.54 μM for TT, TPC1, BCPAP, and K1, respectively <sup>[2]</sup> . ?In macrophages treated with Y15, the filopodia and lamellipodia remain mobile. The lawn of particles surrounding

macrophages appeared larger in cells treated with Y15<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Nude mice bearing Panc si-ctrl xenografts are treated with TAE226, a dual FAK and IGF-1R tyrosine kinase inhibitor, to provide a reference for the antitumor effect of dual inhibition of FAK and IGF-1R. Without drug treatment, Panc si5-IGF-1R xenografts grew slower than Panc si-ctrl xenografts (Panc si5-IGF-1R/PBS vs. Panc si-ctrl/PBS), suggesting moderate tumor suppression by inhibiting the IGF-1R pathway only. Further inhibition of FAK activity by Y15 treatment suppresses the growth of Panc si5-IGF-1R xenografts more drastically (Panc si5-IGF-1R/PBS vs. Panc si5-IGF-1R/Y15). A similar antitumor effect is seen in Panc si-ctrl xenografts treated with TAE226 (Panc si5-IGF-1R/Y15 vs. Panc si-ctrl/TAE226). Mice demonstrates normal grooming and eating habits throughout the experiment<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Kinase Assay <sup>[1]</sup>

10  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P]-ATP in a kinase buffer 20 mM HEPES, pH 7.4, 5 mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.1 mM Na<sub>3</sub>VO<sub>4</sub> with 0.1  $\mu$ g of purified FAK protein are incubated in a kinase buffer with 10  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P]-ATP. The kinase reaction is performed for 5 minutes at room temperature and stopped by addition of 2 $\times$  Laemmli buffer. Proteins are separated on a Ready SDS-10% PAGE gel, and the phosphorylated enolase is visualized by autoradiography<sup>[1]</sup>

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Assay <sup>[1]</sup>

The cells are treated with Y15 or TAE226 at different concentrations for 24 hours. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium compound from Promega Viability kit is added, and the cells are incubated at 37°C for 1-2 hours. The optical density on 96-plate is analyzed with a microplate reader at 490 nm to determine cell viability. In addition, cells are stained with trypan blue after 24 hours of treatment with Y15 and the percent of cells that stained positive are determined with a hemacytometer<sup>[1]</sup>

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration <sup>[3]</sup>

Mice<sup>[3]</sup>

Six-week-old, female nude mice are used. 5 $\times$ 10<sup>6</sup> Panc si5-IGF-1R cells are mixed with matrigel and injected subcutaneously into the flank of athymic nude mice (day 0). Animals are randomly divided into two groups on day 7. One group (n=5) received Y15 (30 mg/kg) and the other received PBS as control treatment (n=5). For Panc si-ctrl xenografts, 5 $\times$ 10<sup>6</sup> Panc si-ctrl cells are mixed with matrigel and injected subcutaneously into the flank of nude mice. These animals are also randomly divided into two groups on day 7, and one group (n=5) received TAE226 (30 mg/kg), the other group received PBS (n=5) as control treatment. The drugs and PBS are administered through intraperitoneal injection in a total volume of 0.1 mL. Tumor sizes are measured every 3 or 4 d in length (mm) $\times$ width (mm) starting from day 10. Tumor volume is calculated as volume (cm<sup>3</sup>)= 1/2 $\times$ length (cm) $\times$ width(cm)<sup>2</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- NPJ Precis Oncol. 2023 Aug 11;7(1):74.
- Stem Cell Res Ther. 2021 Oct 7;12(1):523.
- Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696.
- Front Cell Dev Biol. 2021 May 28;9:607001.
- Atherosclerosis. 2023 Jun 23.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. Xuchen Hu, et al. Release of cholesterol-rich particles from the macrophage plasma membrane during movement of filopodia and lamellipodia. *Elife*. 2019 Sep 5;8:e50231.
- [2]. Hochwald SN, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. *Cell Cycle*. 2009 Aug;8(15):2435-43.
- [3]. O'Brien S, et al. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. *Oncotarget*. 2014 Sep 15;5(17):7945-59.
- [4]. Zheng D, et al. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. *Mol Carcinog*. 2010 Feb;49(2):200-9.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA